ArticleHeart (British Cardiac Society)2024
Beta-blockers and renin-angiotensin system inhibitors for Takotsubo syndrome recurrence: a network meta-analysis.
Article in Heart (British Cardiac Society), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Takotsubo Syndrome: Clinical and Diagnostic Characteristics of 26 Consecutively Hospitalized Patients Over a Five-Year Period.Cardiology research · 2026Article
- Apical Takotsubo Syndrome After Elective Stenting of the Left Anterior Descending Artery.JACC. Case reports · 2026Article
- Various Psychiatric Comorbidities and Smoking Appear to be Associated With Takotsubo Cardiomyopathy: A Nationwide Analysis From 2016 to 2022.Critical pathways in cardiology · 2026Observational
- The Role of Inflammation in Takotsubo Syndrome: From Pathogenic Pathways To Imaging Insights and Therapeutic Perspectives.Current cardiology reports · 2026Review
- Cardiogenic Shock Due to Inverted-Pattern Takotsubo Syndrome Caused by Pheochromocytoma: Case Report and Literature Review.Arquivos brasileiros de cardiologia · 2026Article
- Recovery beyond ejection fraction after takotsubo syndrome: a multidimensional framework for risk-enriched follow-up.Frontiers in cardiovascular medicine · 2026Review
- Takotsubo Cardiomyopathy: An Exploration of the Intersection Between Stress, Coronary Dysfunction, and Cardiac Outcomes.Reviews in cardiovascular medicine · 2025Review
- Steroid-Induced Takotsubo Cardiomyopathy in a Patient With Immune Thrombocytopenic Purpura.Clinical case reports · 2025Article
- Recurrent Takotsubo Cardiomyopathy With Variable Patterns and Psychiatric Comorbidities: A Case Report and Comprehensive Literature Review.Clinical case reports · 2025Article
- Survival benefit of secondary prevention medical therapy in takotsubo cardiomyopathy: a Bayesian network meta-analysis.European heart journal open · 2025Article
- Takotsubo Syndrome: An International Expert Consensus Report on Practical Challenges and Specific Conditions (Part-1: Diagnostic and Therapeutic Challenges)Balkan medical journal · 2024Article
- Recurrent Takotsubo Syndrome Resulting From Different Emotional Triggers as Broken and Happy Heart Syndrome.JACC. Case reports · 2024Article
- Long-Term Functional Limitations on Cardiopulmonary Exercise Testing in Emotion-Triggered Takotsubo Syndrome.Journal of clinical medicine · 2024Article
- Case Report: Asymptomatic SARS-COV2 infection triggering recurrent Takotsubo syndrome.Frontiers in cardiovascular medicine · 2024Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
15 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTakotsubo syndrome (TTS) is an acute heart failure syndrome, featured by transient left ventricular systolic dysfunction. Recurrences of TTS are not infrequent and there is no standard preventive therapy. The aim of this study was to evaluate in a network meta-analysis if beta-blockers (BB) and ACE inhibitors/angiotensin receptor blockers (ACEi/ARBs), in combination or not, can effectively prevent TTS recurrences.
methodsWe performed a systematic network meta-analysis, using MEDLINE/EMBASE and the Cochrane Central Register of Controlled Trials for clinical studies published between January 2010 and September 2022. We considered all those studies including patients receiving medical therapy with BB, ACEi/ARBs. The primary outcome was TTS recurrence.
resultsWe identified 6 clinical studies encompassing a total of 3407 patients with TTS. At 40±10 months follow-up, TTS recurrence was reported in 160 (4.7%) out of 3407 patients. Mean age was 69.8±2 years and 394 patients (11.5%) out of 3407 were male. There were no differences in terms of TTS recurrence when comparing ACEi/ARBs versus control (OR 0.83; 95% CI 0.47 to 1.47, p=0.52); BB versus control (OR 1.01; 95% CI 0.63 to 1.61, p=0.96) and ACEi/ARBs versus BB (OR 0.88; 95% CI 0.51 to 1.53, p=0.65).Combination of BB and ACEi/ARBs was also not effective in reducing the risk of recurrence versus control (OR 0.91; 95% CI 0.58 to 1.43, p=0.68) vs ACEi/ARBs (OR 0.79; 95% CI 0.46 to 1.34, p=0.38)) and vs BB (OR 0.77; 95% CI 0.49 to 1.21, p=0.26).
conclusionsOur study did not find sufficient statistical evidence regarding combination therapy with BB and ACEi/ARBs in reduction of TTS recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.